Pazotab 200 MG (Pazopanib) Tablets

Introduction

The Pazotab 200 mg (Pazopanib) Tablet is a targeted tyrosine kinase inhibitor designed for the treatment of advanced renal cell carcinoma (RCC). Manufactured by Eskayef Pharmaceuticals Ltd., a globally recognized leader in pharmaceutical excellence, and supplied by Onco Solution, a trusted international oncology medicine provider, this tablet offers multi-receptor inhibitory action to combat tumor growth and angiogenesis. With its proven efficacy and patient-centric formulation, the Pazotab 200 mg (Pazopanib) Tablet stands as a reliable therapeutic choice for healthcare professionals and patients seeking advanced RCC management.

Key Benefits

Multi-Targeted Therapy – Inhibits critical receptors like VEGFR, PDGFR, FGFR, and Kit to disrupt tumor blood supply and progression.
Clinically Validated – Supported by preclinical studies demonstrating reduced tumor growth in human xenograft models.
Global Accessibility – Supplied by Onco Solution to ensure affordable, high-quality oncology care worldwide.

Indications

The Pazotab 200 mg (Pazopanib) Tablet is indicated for the treatment of advanced renal cell carcinoma (RCC), making it a cornerstone in metastatic kidney cancer therapy.

Dosage and Administration

Recommended Dose: 800 mg (4 tablets of 200 mg) taken orally once daily on an empty stomach (1 hour before or 2 hours after meals).
Important Guidelines:
- Do not crush or split tablets to avoid altered absorption rates.
- Skip a missed dose if the next dose is due within 12 hours.
- Adjust dosage under medical supervision when using CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin).

Safety and Precautions

Common Side Effects

Gastrointestinal issues (diarrhea, nausea, vomiting).
Hypertension and hair depigmentation.

Severe Risks

Hepatotoxicity: Regular liver function monitoring is mandatory. Discontinue use if severe liver injury occurs.
QT Prolongation: Use cautiously in patients with cardiac history; monitor ECG and electrolytes.
Hemorrhage: Contraindicated in patients with recent bleeding episodes (e.g., hemoptysis, GI hemorrhage).

Drug Interactions

CYP3A4 Modulators: Avoid strong inhibitors (e.g., clarithromycin) or inducers (e.g., phenytoin). Adjust Pazopanib dose to 400 mg if co-administered with inhibitors.
Simvastatin: Increases risk of ALT elevation; monitor liver enzymes.
Antacids/PPIs: Separate dosing by several hours to avoid reduced Pazopanib absorption.

Pregnancy and Lactation

Pregnancy: Contraindicated due to fetal risk. Women of childbearing potential must use contraception during treatment.
Lactation: Discontinue breastfeeding or medication to prevent potential harm to infants.

Why Choose Pazotab 200 mg (Pazopanib) Tablet?

Trusted Manufacturer: Produced by Eskayef Pharmaceuticals Ltd., a pioneer in Bangladesh’s pharmaceutical industry with over 30 years of expertise in quality medicine production.
Global Supplier Partnership: Supplied by Onco Solution, a leader in affordable oncology solutions, ensuring access to life-saving treatments across Asia, Africa, and Europe.
Comprehensive Support: Onco Solution provides resources, treatment guidance, and connects patients to a global network of oncology specialists.

Technical Specifications

Active Ingredient: Pazopanib Hydrochloride (200 mg per tablet).
Storage: Store below 30°C in a dry, light-protected environment.
Packaging: Sealed blister packs to ensure stability and potency.

Commitment to Excellence

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s esteemed Transcom Group, combines innovation with stringent quality standards. Collaborating with Onco Solution, they deliver affordable, high-efficacy oncology treatments to bridge global healthcare gaps.

Conclusion

The Pazotab 200 mg (Pazopanib) Tablet represents a critical advancement in renal cell carcinoma therapy, offering targeted action, safety, and global accessibility. By choosing this product, healthcare providers and patients align with Eskayef Pharmaceuticals Ltd. and Onco Solution – leaders committed to advancing cancer care through innovation and compassion.